Trials / Unknown
UnknownNCT03933319
Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Chinese Academy of Medical Sciences · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-center phase Ⅱ study designed to evaluated the efficacy and safety of pegylated liposomal doxorubicin（PLD）in combination with trastuzumab in HER-2 positive metastatic breast cancer .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pegylated liposomal doxorubicin | Eligible patients will be treated with the PLD+trastuzumab regimen until the disease progresses or intolerable toxicity |
Timeline
- Start date
- 2019-03-11
- Primary completion
- 2021-03-31
- Completion
- 2022-05-01
- First posted
- 2019-05-01
- Last updated
- 2020-07-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03933319. Inclusion in this directory is not an endorsement.